Table 2 Summary of the clinical response
Ceftriaxone-sulbactam | Cefoperazone-sulbactam | P | |
|---|---|---|---|
Clinical response in total at the end of therapy, n(%) | 134 | 129 | |
Cure | 53(39.55) | 47(36.43) | 0.6138 |
Cure + marked improvement | 114(85.07) | 103(79.84) | 0.3300 |
Improvement + failure | 20(14.93) | 26(20.16) | |
Clinical response for RTIs at the end of therapy, n(%) | 65 | 65 | |
Cure | 18(27.69) | 13(20.00) | 0.4107 |
Cure + marked improvement | 50(76.92) | 46(70.77) | 0.5398 |
Improvement + failure | 15(23.08) | 19(29.23) | |
Clinical response for UTIs at the end of therapy, n(%) | 69 | 64 | |
Cure | 35(50.72) | 34(53.13) | 0.8626 |
Cure + marked improvement | 64(92.75) | 57(89.06) | 0.5513 |
Improvement + failure | 5(7.25) | 7(10.94) | |
Clinical response caused by gram-negative germs at the end of therapy, n(%) | 129 | 120 | |
Cure | 53(41.09) | 44(36.67) | 0.5166 |
Cure + marked improvement | 112(86.82) | 94(78.33) | 0.0935 |
Improvement + failure | 17(13.18)13.18 | 26(21.67) | |
Clinical response caused by gram-positive germs at the end of therapy, n(%) | 5 | 9 | |
Cure | 0(0.00) | 3(33.33) | 0.2582 |
Cure + marked improvement | 2(40) | 9(100) | 0.0275 |
Improvement + failure | 3(60) | 0(0) | |
Clinical response in total at the day 7 follow-up visit | 114 | 103 | |
Continued resolution n(%) | 114(100) | 103(100) | |
Relapse n(%) | 0(0) | 0(0) |